In its maiden M&A deal, SOPHiA Genetics has acquired Interactive Biosoftware (IBS), the French tech developer of Alamut, a suite of clinical decision applications for genomic analysis, for an undisclosed price. The Swiss analytics company said the acquisition is aimed at accelerating the adoption of its artificial intelligence (AI) platform for cancer diagnosis.
IBS' Alamut software suite includes Alamut Batch, an annotation software for next generation sequencing (NGS) analysis; Alamut Focus, a variant filtration application created to let users put forward genetic variations of interest; and Alamut Visual, a graphical software application designed to enable interactive exploration of genetic variants. The technology is currently used in more than 450 hospitals which will now join SOPHiA's clinical community.
SOPHIA Genetics told Medtech Insight the Alamut technology complemented its clinical platform, which uses AI to analyze circulating tumor DNA (ctDNA), contained in patients’ fluid samples such as blood, urine, and cerebral spinal fluid. The blood samples are first processed using a DNA sequencer, and the data yielded from the genomic sequencing is then entered into the company's online analytical platform SOPHiA DDM, which uses AI algorithms to identify mutations in the patient's genome. As the user-base and clinical network expands, the AI platform learns from the genomics profiles and improves patient diagnosis.
The company said the integration of Alamut enabled it to provide a more "complete solution" for clinicians performing clinical genomic testing to better diagnose their patients. "First of all, all hospitals who use SOPHiA DDM platform are already using IBS’ Alamut software which makes the integration of both technologies easier, " Gioia Althoff, Sophia Genetics' Senior VP of Genomics told Medtech Insight. "Alamut is the leading device regarding the next step of interpretation: allowing clinicians to go even further in the interpretation of those alterations. As such, Alamut is complementary to SOPHiA’s offering."
"The combination of the two technologies enables SOPHiA GENETICS to continue to provide valuable and performance-enhancing solutions which meet the complex needs of healthcare professionals working in the field of clinical genomics. By offering a more comprehensive solution, including top-notch technology to support them with everything from genomic alteration detection to variant interpretation and treatment decision making, we aim to increase this trust even further."
SOPHiA Genetics has previously outlined its vision to "democratize" data-driven medicine and help oncology enter the era of real-time epidemiology. Earlier this year, the company added new radiomics capabilities to its technology that help monitor disease progression and treatment efficacy by analyzing quantitative image features from standard-of-care medical images such as PET-scans, MRIs and X-rays. (Also see "SOPHiA Genetics Combines In Vivo And In Vitro Cancer Analyses With Enhanced AI Platform" - Medtech Insight, 24 Jan, 2018.)
The venture-backed company has raised around $58.7m so far and announced a $30m Series D funding in September last year, adding UK-based VC firm Balderton Capital to its investor list, along with 360 Capital Partners. Previous investors include UK tech entrepreneur Mike Lynch’s Invoke Capital, and Alychlo, started by Mark Coucke, a Belgian pharmaceutical entrepreneur. The company was recently voted number one on the Disrupt 100, a list of businesses with the most potential to influence, change or create new global markets.